Merck: Molnupiravir Shows Consistent Antiviral Activity Against Omicron In Multiple In Vitro Studies
KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) and Ridgeback Biotherapeutics reported data from six preclinical studies showing that molnupiravir, an investigational oral antiviral COVID-19 medicine,